Genetic prostate cancer screening study aims to catch tumors early
NCT ID NCT00261456
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
The IMPACT study is an international effort to screen men aged 40-69 who carry BRCA1, BRCA2, or mismatch repair gene mutations, which raise their risk of prostate cancer. Participants receive annual PSA tests and optional biopsies if levels are high. The goal is to learn how often prostate cancer is found in these men compared to those without the mutations, and to improve early detection strategies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this study could show that annual PSA screening helps detect prostate cancer earlier in men with certain gene mutations, potentially leading to better outcomes.
What could go wrong
This is an observational screening study, not a treatment trial. It may not prove that screening saves lives, and results may not apply to all men.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Genetics Unit, Royal Marsden Hospital
Sutton, Surrey, SM2 5PT, United Kingdom